Pharma Q4 Results Preview: J&J, Novartis, Celgene, Biogen & AbbVie
Novartis expected to give Joe Jimenez a good farewell gift; AbbVie says it is not planning major M&A to focus on risankizumab and upadacitinib, but Celgene is on the hunt for deals – will Juno be its next big buy?
You may also be interested in...
Patent Trial and Appeal Board finds that the patent covering the blockbuster prostate cancer drug is unpatentable, which could allow generics to launch at-risk in October once they obtain FDA approval; at least 12 firms have pending ANDAs.
Pooling resources appears key to a major new collaboration in the biosimilars space, between Sandoz and India's Biocon, to develop the next generation of biosimilar immunology and oncology products.
Observers are weighing up whether it makes sense for Celgene to spend in the region of $12bn and plump for the promise of Juno's CAR-T program and whether it would be forced to abandon another promising partner in bluebird.